8-OH-PBZI

8-OH-PBZI
(IUPAC) ime
	(3aS,9bR)-3-propil-1,2,3a,4,5,9b-heksahidrobenzo[e]indol-8-ol
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	10353845
ChemSpider	8529297
Hemijski podaci
Formula	C15H21NO
Mol. masa	231,333 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C15H21NO/c1-2-8-16-9-7-13-14-10-12(17)5-3-11(14)4-6-15(13)16/h3,5,10,13,15,17H,2,4,6-9H2,1H3/t13-,15+/m1/s1 ; Key: LJDRQPOQHHOXHM-HIFRSBDPSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

8-OH-PBZI je lek koji se koristi u naučnim istraživanjima. On deluje kao potentan i selektivan agonist dopaminskog D₃ receptora.^[4]^[5]^[6]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Scheideler, MA; Martin, J; Hohlweg, R; Rasmussen, JS; Naerum, L; Ludvigsen, TS; Larsen, PJ; Korsgaard, N i dr.. (1997). „The preferential dopamine D3 receptor agonist cis-8-OH-PBZI induces limbic Fos expression in rat brain”. European journal of pharmacology 339 (2–3): 261–70. DOI:10.1016/S0014-2999(97)01372-1. PMID 9473144.
↑ Fink-Jensen, A; Nielsen, EB; Hansen, L; Scheideler, MA (1998). „Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI”. European journal of pharmacology 342 (2–3): 153–61. DOI:10.1016/S0014-2999(97)01494-5. PMID 9548380.
↑ Malik, P; Andersen, MB; Peacock, L (2004). „The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia”. Pharmacology, biochemistry, and behavior 78 (4): 805–10. DOI:10.1016/j.pbb.2004.05.019. PMID 15301939.

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Scheideler, MA; Martin, J; Hohlweg, R; Rasmussen, JS; Naerum, L; Ludvigsen, TS; Larsen, PJ; Korsgaard, N i dr.. (1997). „The preferential dopamine D3 receptor agonist cis-8-OH-PBZI induces limbic Fos expression in rat brain”. European journal of pharmacology 339 (2–3): 261–70. DOI:10.1016/S0014-2999(97)01372-1. PMID 9473144.

[5] Fink-Jensen, A; Nielsen, EB; Hansen, L; Scheideler, MA (1998). „Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI”. European journal of pharmacology 342 (2–3): 153–61. DOI:10.1016/S0014-2999(97)01494-5. PMID 9548380.

[6] Malik, P; Andersen, MB; Peacock, L (2004). „The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia”. Pharmacology, biochemistry, and behavior 78 (4): 805–10. DOI:10.1016/j.pbb.2004.05.019. PMID 15301939.

[4]

[5]

[6]

[1]

[2]

[3]